Mesentech candidate drug C3 used in peer-reviewed article published by Journal of Oral & Maxillofacial Implants
One of Mesentech's candidate drugs, C3, was used in a new biomaterial. Experimenters at Mount Sinai hospital used a brushite or monetite base with or without C3 implanted onto rabbit calvaria. The grafts containing C3 integrated with new bone extending 80% through the graft area while the C3 lacking grafts showed decreased surface integration of 38%. Moreover, C3 containing grafts had 2.7mm vertical bone augmentation compared to nil for C3 deficient grafts. The advantages of this new graft drug formulation in future would be to provide more predictable vertical bone regeneration, which will ultimately benefit patients undergoing dental implant placement.